OBJECTIVES: The aim of this analysis is to examine the influence of gender differences on the outcome after transcatheter aortic valve implantation (TAVI) from a multicenter real-world registry in Germany (TAVI registry). BACKGROUND: The impact of gender differences on the clinical outcome after TAVI was examined in small studies with conflicting results. METHODS: Consecutive patients (n = 1,432) undergoing TAVI in the period between January 2009 and June 2010 in Germany were evaluated. Differences in all-cause mortality were examined with Kaplan-Meier estimates and proportional hazards models. RESULTS: Women comprised 57.8 % of the cohort. The Edwards Sapien valve (18.5 %) and CoreValve (81.5 %) were used through the transfemoral (87.7 %), subclavian (3.0 %), transapical (8.6 %), or transaortic approach (0.7 %). At baseline, women had higher aortic gradients and were older. Men had more comorbidities: prior myocardial infarction, prior revascularization, prior coronary artery bypass surgery, peripheral arterial vascular disease and chronic obstructive pulmonary disease. Women had more periprocedural vascular complications in comparison to men (25.2 vs. 17.2 %, p < 0.001). There was no significant difference in mortality at 30-day follow-up (7.6 % for women vs. 8.6 % for men, p = 0.55). The adjusted HR for 1-year all-cause mortality favored women, HR 0.75 (95 % CI 0.57-0.98, p = 0.0346) with a mortality rate of 17.3 vs. 23.6 % for men. CONCLUSIONS: Female gender is associated with better 1-year survival after TAVI. These results suggest that TAVI could be the best treatment modality for elderly women with symptomatic severe aortic stenosis.
OBJECTIVES: The aim of this analysis is to examine the influence of gender differences on the outcome after transcatheter aortic valve implantation (TAVI) from a multicenter real-world registry in Germany (TAVI registry). BACKGROUND: The impact of gender differences on the clinical outcome after TAVI was examined in small studies with conflicting results. METHODS: Consecutive patients (n = 1,432) undergoing TAVI in the period between January 2009 and June 2010 in Germany were evaluated. Differences in all-cause mortality were examined with Kaplan-Meier estimates and proportional hazards models. RESULTS:Women comprised 57.8 % of the cohort. The Edwards Sapien valve (18.5 %) and CoreValve (81.5 %) were used through the transfemoral (87.7 %), subclavian (3.0 %), transapical (8.6 %), or transaortic approach (0.7 %). At baseline, women had higher aortic gradients and were older. Men had more comorbidities: prior myocardial infarction, prior revascularization, prior coronary artery bypass surgery, peripheral arterial vascular disease and chronic obstructive pulmonary disease. Women had more periprocedural vascular complications in comparison to men (25.2 vs. 17.2 %, p < 0.001). There was no significant difference in mortality at 30-day follow-up (7.6 % for women vs. 8.6 % for men, p = 0.55). The adjusted HR for 1-year all-cause mortality favored women, HR 0.75 (95 % CI 0.57-0.98, p = 0.0346) with a mortality rate of 17.3 vs. 23.6 % for men. CONCLUSIONS: Female gender is associated with better 1-year survival after TAVI. These results suggest that TAVI could be the best treatment modality for elderly women with symptomatic severe aortic stenosis.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Karin H Humphries; Stefan Toggweiler; Josep Rodés-Cabau; Luis Nombela-Franco; Eric Dumont; David A Wood; Alexander B Willson; Ronald K Binder; Melanie Freeman; May K Lee; Min Gao; Mona Izadnegahdar; Jian Ye; Anson Cheung; John G Webb Journal: J Am Coll Cardiol Date: 2012-07-18 Impact factor: 24.094
Authors: Lutz Buellesfeld; Stefan Stortecky; Bindu Kalesan; Steffen Gloekler; Ahmed A Khattab; Fabian Nietlispach; Valentina Delfine; Christoph Huber; Balthasar Eberle; Bernhard Meier; Peter Wenaweser; Stephan Windecker Journal: JACC Cardiovasc Interv Date: 2013-01 Impact factor: 11.195
Authors: Marcel Weber; Eva Brüggemann; Robert Schueler; Diana Momcilovic; Jan-Malte Sinning; Alexander Ghanem; Nikos Werner; Eberhard Grube; Wolfgang Schiller; Fritz Mellert; Armin Welz; Georg Nickenig; Christoph Hammerstingl Journal: Clin Res Cardiol Date: 2015-05-13 Impact factor: 5.460
Authors: Janine Biermann; Martin Horack; Philipp Kahlert; Steffen Schneider; Georg Nickenig; Ralf Zahn; Jochen Senges; Raimund Erbel; Jürgen Wasem; Till Neumann Journal: Clin Res Cardiol Date: 2015-04-21 Impact factor: 5.460
Authors: Alberto Ranieri De Caterina; Jens Erik Nielsen-Kudsk; Boris Schmidt; Patrizio Mazzone; Sven Fischer; Juha Lund; Matteo Montorfano; Ryan Gage; Simon Cheung Chi Lam; Sergio Berti Journal: Int J Cardiol Heart Vasc Date: 2021-07-26